ArticleFrontiers in genetics2026
A 3'UTR polymorphism disrupts IRF2BP2 autoregulation through an eIF4H translational enhancer.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Interferon regulatory factor 2 binding protein 2 (IRF2BP2) suppresses the interferon response and inflammation. Individuals who carry 2 copies of a genetic variant (rs3045215) that deletes 9 nucleotides from the long 3'UTR of IRF2BP2 have lower IRF2BP2 protein expression in white blood cells and increased risk of coronary atherosclerosis and calcification. Methods and Results: RNAfold revealed that the deletion variant of IRF2BP2 disrupts an RNA stem-loop structure that can recruit the eukaryotic initiation factor 4H (eIF4H) to facilitate translation. siRNA knockdown of eIF4H reduced expression of endogenous IRF2BP2 protein. Similarly, it impaired translation of a luciferase reporter bearing the whole 3'UTR of IRF2BP2 but had no effect on one bearing the 9-nucleotide deletion variant (rs3045215). This deletion variant happens to be co-inherited with an IRF2BP2 coding variant that changes proline to serine at position 78. Overexpression of either isoform of IRF2BP2 (Pro Conclusion: The rs3045215 9-nucleotide deletion that increases the risk of heart disease abolishes IRF2BP2 autoregulation through an eIF4H-dependent translational enhancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.